Enter psychedelics like ketamine, psilocybin, and MDMA, which are being explored as tools to access and process these buried ...

The expansion is effective immediately, nearly one year after NeuroStar ® Advanced Therapy received FDA clearance as the first first-line add-on treatment for adolescents aged 15-21 with MDD. In the ...

Treatment-Resistant Depression (TRD), a new option is available through Blessing’s Outpatient Behavioral Health ...

Tesla and SpaceX CEO Elon Musk clarified that he uses only "a small amount once every other week or something like that" ...

Discover recent clinical trial failures in depression and explore potential pathways for advancing antidepressant drug ...

HOPE Therapeutics, wholly owned by NRx Pharmaceuticals (NRXP), announced signing of a binding Letter of Intent, LOI, to acquire a majority ...

In terms of the newest collaboration, the health care professionals said they decided that having all the services under one ...

Q4 2024 Earnings Call Transcript March 17, 2025 Operator: Good morning, ladies and gentlemen, and welcome to the NRx Pharmaceuticals 4Q and Full Year 2024 Earnings Call. At this time, all lines are in ...

Myers Squibb Company, Johnson & Johnson, Bausch Health Companies Inc, AbbVie Inc. Read 's Market Analysis on Investing.com ...

However, Medicare may cover the drug Spravato, which contains esketamine. This is an FDA-approved drug that derives from ketamine and may help treatment-resistant depression. Although the FDA has ...

Spravato (esketamine) is prescribed for adults to treat: major depressive disorder (MDD), also called depression, with suicidal thoughts or actions treatment-resistant depression For MDD ...